Retos de hoy en Medicina Intensiva: diversidad, equidad e inclusión. Posicionamiento de género de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) / Challenges in intensive medicine: Diversity, equity and inclusion. Gender statement of the Spanish Society of Intensive and Critical Medicine and Coronary Units (SEMICYUC)

El género es un determinante social que impacta en el ámbito de la salud y genera desigualdades a todos los niveles; repercute en los pacientes y en la patología crítica, en los profesionales y en el desarrollo de la carrera profesional y las sociedades científicas, desde una perspectiva de justicia social. Todas las sociedades científicas internacionales de medicina intensiva comprometidas en aportar una perspectiva de género coinciden en la necesidad de un compromiso formal por parte de las instituciones. La Sociedad de Medicina Intensiva y Unidades Coronarias (SEMICYUC) se compromete a velar por la equidad, la inclusión y la representatividad de sus profesionales y combatir la brecha de género en el ámbito de la medicina intensiva (AU)

Gender is a social determinant that impacts on health and generates inequities at all levels; it has an impact on patients and critical pathology, professionals and professional career development, and scientific societies, from a social justice perspective. All the international scientific societies of Intensive Care Medicine committed to contributing a gender perspective agree on the need for a formal positioning by the institutions. The Society of Intensive Medicine and Coronary Units (SEMICYUC) is committed to ensuring the equity, inclusion and representativeness of its professionals and combating the gender gap in the field of Intensive Medicine (AU)

Challenges in intensive medicine: Diversity, equity and inclusion. Gender statement of the Spanish Society of Intensive and Critical Medicine and Coronary Units (SEMICYUC).

Gender is a social determinant that impacts health and generates inequalities at all levels. It has impacts patients and critical conditions, health professionals and professional career development, and scientific societies from a perspective of social justice. All the International scientific societies of Intensive Care Medicine committed to contributing a gender perspective agree on the institutional need for achieving a formal positioning standpoint. The Spanish Society of Intensive and Critical Medicine and Coronary Units (SEMICYUC) is committed to ensuring the equality, inclusion and representativeness of its health professionals to fight the existing gender gap in the field of Intensive Medicine.

Correlation between Thyroid Responses and Inflammatory Cytokines in Critically Ill COVID-19 Patients.

Mechanisms involved in thyroid dysfunction in critically ill coronavirus disease 2019 (COVID-19) patients are not clear. Our objective was to correlate the thyroid response with the pro- and anti-inflammatory cytokines profile in critically ill COVID-19 patients. This was a prospective single-center study. We studied the relationship between continuous variables by using Pearson correlation and simple linear regression. Multiple logistic regression analysis was performed to analyze the factors independently associated with mortality. Seventy-eight patients were included in the study at intensive care unit (ICU) admission and 72 had a measurement of the thyroid and inflammatory profile at day 5. No significant correlations were found between thyroid stimulating hormone (TSH), free triiodothyronine (fT3) and free thyroxine (fT4) and inflammatory cytokines at ICU admission. At day 5, fT4, was inversely correlated with IL-10 (p = 0.035). IL-10 was associated with maximum lactate (p < 0.001) and SOFA score values (p = 0.012). The multiple logistic regression analysis showed that there was a significant relationship between IL-10 (day 5) and in-hospital mortality after adjusting by age and severity of illness. In conclusion, we found that the thyroid hormone profile and inflammatory cytokines had a weak correlation at ICU admission. Associations of interest between fT4 and IL-10 were found at day 5. IL-10 at day 5 was found to be correlated with low fT4 and markers of organ failure and death.

Concomitant Traumatic Brain Injury and Hemorrhagic Shock: Outcomes Using the Spanish Trauma ICU Registry (RETRAUCI).

BACKGROUND: To compare the main outcomes of trauma patients with and without traumatic brain injury (TBI), hemorrhagic shock, and the combination of both using data from the Spanish trauma intensive care unit (ICU) registry (RETRAUCI). METHODS: Patients admitted to the participating ICUs from March 2015 to May 2019 were included in the study. The main outcomes were analyzed according to the presence of TBI, hemorrhagic shock, and/or both. Comparison of groups with quantitative variables was performed using the Kruskal-Wallis test, and differences between groups with categorical variables were compared using the Chi-square test or Fisher's exact test as appropriate. A P value <.05 was considered significant. RESULTS: Overall, 310 patients (3.98%) were presented with TBI and hemorrhagic shock. Patients with TBI and hemorrhagic shock received more red blood cell (RBC) concentrates, fresh frozen plasma (FFP), a higher ratio FFP/RBC, and had a higher incidence of trauma-induced coagulopathy (60%) (P < .001). These patients had higher mortality (P < .001). Intracranial hypertension was the leading cause of death (50.4%). CONCLUSIONS: Concomitant TBI and hemorrhagic shock occur in nearly 4% of trauma ICU patients. These patients required a higher amount of RBC concentrates and FFP and had an increased mortality.

Risk Factors Associated With Early and Late Posttraumatic Multiorgan Failure: An Analysis From RETRAUCI.

OBJECTIVE: To analyze factors associated with the development of early and late multiorgan failure (MOF) in trauma patients admitted to the intensive care unit (ICU). METHODS: Spanish Trauma ICU Registry (RETRAUCI). Data collected from 52 trauma ICU between March 2015 and December 2019. We analyzed the incidence, outcomes, and the risk factors associated with early (< 72 h) or late (beyond 72 h) MOF in trauma ICU patients. Multiple logistic regression analysis was performed to analyze associated factors. RESULTS: After excluding patients with incomplete data, 9,598 trauma ICU patients constituted the study population. Up to 965 patients (10.1%) presented with MOF, distributed by early MOF in 780 patients (8.1%) and late MOF in 185 patients (1.9%). The multivariate analysis showed that early MOF was associated with: ISS ≥ 16 (OR 2.80), hemodynamic instability (OR from 2.03 to 43.05), trauma-associated coagulopathy (OR 2.32), and acute kidney injury (OR 4.10). Late MOF was associated with: age > 65 years (OR 1.52), hemodynamic instability (OR from 1.92 to 9.94), acute kidney injury (OR 4.22), and nosocomial infection (OR 17.23). MOF was closely related to mortality (crude OR (95% CI) 4.77 (4.22-5.40)). CONCLUSIONS: Multiorgan failure was recorded in 10% of trauma ICU patients, with early MOF being the predominant form. Early and late MOF forms were associated with different risk factors, suggesting different pathophysiological pathways. Early MOF was associated with higher severity of injury and severe bleeding-related complications and late MOF with advanced age and nosocomial infection.

Solución tamponada frente a solución salina al 0.9% en adultos y niños gravemente enfermos / Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children

FUNDAMENTO: La terapia de fluidos intravenosos sirve como piedra angular del tratamiento de un amplio espectro de enfermedades graves. Conocer su impacto en términos de resultados clínicos es una cuestión importante. Existen algunas dudas sobre si el uso de una solución salina al 0,9%puede causar mayor mortalidad entre pacientes hospitalizados o un empeoramiento relevante de su función renal. El objetivo de esta revisión Cochrane fue averiguar si la fluidoterapia con soluciones tamponadas (solución salina a base de agua con un búfer para mantener un pH constante) daba como resultado menos muertes en el hospital y menos daño en los riñones de adultos y niños gravemente enfermos, en comparación con la solución salina al 0,9%. CARACTERÍSTICAS DE LOS ESTUDIOS: Se encontraron 21 estudios realizados tanto en niños como en adultos, con un total de 20.213 participantes. Estos estudios compararon las soluciones tamponadas con las soluciones salinas al 0,9% para adultos y niños gravemente enfermos (incluidos aquellos con sepsis, traumatismos, quemaduras o conmoción) a quienes no se les había realizado una cirugía planificada. Se excluyeron los ensayos en los que los participantes recibieron una cirugía planificada (electiva). Estos estudios se realizaron en 13 países. FUENTES DE FINANCIACIÓN: Doce de los estudios incluidos fueron financiados por gobiernos u organizaciones sin ánimo de lucro, 2 recibieron financiación mixta, uno fue financiado por una empresa cuyo papel en el estudio no se aclaró, y 6 no proporcionaron detalles. Resultados principales. Las soluciones tamponadas no parecen reducir las muertes hospitalarias o el empeoramiento de la función renal (del riñón) en adultos y niños gravemente enfermos, en comparación con la solución salina al 0,9%. La revisión muestra que, en comparación con los pacientes que recibieron soluciones salinas al 0,9%: 1) las soluciones tamponadas tuvieron poca o ninguna repercusión en la mortalidad general (19.664 participantes; 14 estudios; evidencia de calidad alta); 2) las soluciones tamponadas probablemente pueden tener poco o ningún efecto en la reducción del número de pacientes con empeoramiento de la función renal (18.701participantes; 9 estudios; evidencia de calidad baja); y 3) no hay certeza de que las soluciones tamponadas reduzcan el deterioro funcional de otros órganos (por ejemplo, pulmonar, hepática o cerebral), las alteraciones electrolíticas (aumento o disminución del cloruro o el sodio u otras sales)y la necesidad de recibir transfusiones de sangre, porque la calidad de la evidencia es muy baja. Ninguno de los estudios examinó la pérdida de sangre, los trastornos de la coagulación (en relación con el riesgo de hemorragias o coágulos) y la calidad de vida. Los resultados variaron en cuanto a los puntos temporales en los que se informaron, la unidad de medida utilizada y las medidas informadas. No se registró la cantidad total de líquido administrado durante la terapia de fluidos. Solo 4 estudios incluyeron niños. Estos niños estaban menos enfermos que los participantes incluidos en los ensayos con adultos, y no se informó sobre el daño renal. Los 3 estudios en curso, una vez publicados y evaluados, pueden alterar las conclusiones de esta revisión. ¿Cómo de actual es esta revisión? Se buscaron los estudios publicados hasta julio de 2018

No disponible

Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children.

BACKGROUND: Fluid therapy is one of the main interventions provided for critically ill patients, although there is no general consensus regarding the type of solution. Among crystalloid solutions, 0.9% saline is the most commonly administered. Buffered solutions may offer some theoretical advantages (less metabolic acidosis, less electrolyte disturbance), but the clinical relevance of these remains unknown. OBJECTIVES: To assess the effects of buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children. SEARCH METHODS: We searched the following databases to July 2018: CENTRAL, MEDLINE, Embase, CINAHL, and four trials registers. We checked references, conducted backward and forward citation searching of relevant articles, and contacted study authors to identify additional studies. We imposed no language restrictions. SELECTION CRITERIA: We included randomized controlled trials (RCTs) with parallel or cross-over design examining buffered solutions versus intravenous 0.9% saline in a critical care setting (resuscitation or maintenance). We included studies on participants with critical illness (including trauma and burns) or undergoing emergency surgery during critical illness who required intravenous fluid therapy. We included studies of adults and children. We included studies with more than two arms if they fulfilled all of our inclusion criteria. We excluded studies performed in persons undergoing elective surgery and studies with multiple interventions in the same arm. DATA COLLECTION AND ANALYSIS: We used Cochrane's standard methodological procedures. We assessed our intervention effects using random-effects models, but when one or two trials contributed to 75% of randomized participants, we used fixed-effect models. We reported outcomes with 95% confidence intervals (CIs). MAIN RESULTS: We included 21 RCTs (20,213 participants) and identified three ongoing studies. Three RCTs contributed 19,054 participants (94.2%). Four RCTs (402 participants) were conducted among children with severe dehydration and dengue shock syndrome. Fourteen trials reported results on mortality, and nine reported on acute renal injury. Sixteen included trials were conducted in adults, four in the paediatric population, and one trial limited neither minimum or maximum age as an inclusion criterion. Eight studies involving 19,218 participants were rated as high methodological quality (trials with overall low risk of bias according to the domains: allocation concealment, blinding of participants/assessors, incomplete outcome data, and selective reporting), and in the remaining trials, some form of bias was introduced or could not be ruled out.We found no evidence of an effect of buffered solutions on in-hospital mortality (odds ratio (OR) 0.91, 95% CI 0.83 to 1.01; 19,664 participants; 14 studies; high-certainty evidence). Based on a mortality rate of 119 per 1000, buffered solutions could reduce mortality by 21 per 1000 or could increase mortality by 1 per 1000. Similarly, we found no evidence of an effect of buffered solutions on acute renal injury (OR 0.92, 95% CI 0.84 to 1.00; 18,701 participants; 9 studies; low-certainty evidence). Based on a rate of 121 per 1000, buffered solutions could reduce the rate of acute renal injury by 19 per 1000, or result in no difference in the rate of acute renal injury. Buffered solutions did not show an effect on organ system dysfunction (OR 0.80, 95% CI 0.40 to 1.61; 266 participants; 5 studies; very low-certainty evidence). Evidence on the effects of buffered solutions on electrolyte disturbances varied: potassium (mean difference (MD) 0.09, 95% CI -0.10 to 0.27; 158 participants; 4 studies; very low-certainty evidence); chloride (MD -3.02, 95% CI -5.24 to -0.80; 351 participants; 7 studies; very low-certainty evidence); pH (MD 0.04, 95% CI 0.02 to 0.06; 200 participants; 3 studies; very low-certainty evidence); and bicarbonate (MD 2.26, 95% CI 1.25 to 3.27; 344 participants; 6 studies; very low-certainty evidence). AUTHORS' CONCLUSIONS: We found no effect of buffered solutions on preventing in-hospital mortality compared to 0.9% saline solutions in critically ill patients. The certainty of evidence for this finding was high, indicating that further research would detect little or no difference in mortality. The effects of buffered solutions and 0.9% saline solutions on preventing acute kidney injury were similar in this setting. The certainty of evidence for this finding was low, and further research could change this conclusion. Patients treated with buffered solutions showed lower chloride levels, higher levels of bicarbonate, and higher pH. The certainty of evidence for these findings was very low. Future research should further examine patient-centred outcomes such as quality of life. The three ongoing studies once published and assessed may alter the conclusions of the review.

Buffered Solutions Versus Isotonic Saline for Resuscitation in Nonsurgical Critically Ill: Protocol for Cochrane Review.

Fluid resuscitation is one of the most prevalent treatment in critical care. There is not definitive evidence about the best fluid for resuscitation. The aim of this review will be to asses the efficacy and safety of buffered solution versus saline. We will perform an electronic search in Medline, Embase, and Central. Studies will be eligible if they are clinical trials who including critical ill patients. Primary outcomes are mortality and renal failure. All findings will be tabulated and synthesized. We will perform a meta-analysis according to Cochrane Review standards. We will design a summary of findings table.